特应性皮炎生物制剂延长给药间隔:为何、何人、何时与如何
本文综述特应性皮炎生物制剂延长给药间隔的策略与证据。在正式临床试验和真实世界实践中,相当比例患者可在延长间隔下维持疾病控制,临床预测因素正在显现,但延长间隔对副作用的缓解作用尚缺乏证据。建议疾病控制良好的患者通过医患共同决策实现个体化给药。
要点
- 部分特应性皮炎患者可在延长生物制剂给药间隔后维持疾病控制。
- 延长给药间隔的临床预测因素正在研究中,证据尚不充分。
- 疾病控制良好者适合通过医患共同决策制定个体化给药方案。
核心结论
- 在多样化研究背景下,存在大量患者能在延长给药间隔下维持 adequate 疾病控制。
- 延长给药间隔作为减轻副作用策略的证据尚缺乏。
- 疾病控制良好的患者是医患共同决策个体化给药的理想候选。
研究设计与样本
- 本文为综述,汇总正式临床试验和真实世界临床实践中生物制剂延长给药间隔的研究进展与证据。
主要发现
- 在正式临床试验和真实世界临床实践中均开展了延长给药间隔的研究。
- 相当比例患者可在延长给药间隔下维持 adequate 疾病控制。
- 维持疾病控制的临床预测因素证据正在显现。
- 延长给药间隔对副作用影响的研究证据缺乏。
临床怎么用
- 对疾病控制良好的特应性皮炎患者,可考虑医患共同决策制定个体化延长给药间隔方案。
局限性
- 延长给药间隔作为减轻副作用策略的证据缺乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biologics approved and in development for atopic dermatitis offer life-changing clinical efficacy with a relatively banal long-term safety profile requiring no laboratory monitoring. Biologic therapies also have their drawbacks, including high payor cost and the need to be administered as every other week subcutaneous injections. Addressing these concerns, studies of longer dosing intervals have been performed in the formal clinical trial setting and during real-world clinical care. Here, we review the current progress and evidence of dose elongation strategies in biologics for atopic dermatitis. We find that across a diverse investigational landscape, a large patient population exists that is able to maintain adequate disease control on a prolonged dosing interval. Evidence of clinical predictors of maintenance of disease control using this approach is emerging, although the impact of increased dosing intervals as a strategy to mitigate side effects is lacking. Patients experiencing good disease control are ideal candidates to engage in a shared decision-making process between patients and providers that will facilitate an individualized dosing approach in practice.
引用
- Jacobson ME, Boesjes CM, de Bruin-Weller MS, et al. Increasing dosing intervals for biologics in atopic dermatitis-why, who, when and how? J Eur Acad Dermatol Venereol. 2025. PMID: 39840710. doi:10.1111/jdv.20534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。